- Home
- LIXT vs FTFT Comparison
LIXT vs FTFT Comparison
Compare LIXT & FTFT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LIXT
- FTFT
- Stock Information
- Founded
- LIXT 2005
- FTFT N/A
- Country
- LIXT United States
- FTFT United States
- Employees
- LIXT N/A
- FTFT N/A
- Industry
- LIXT Biotechnology: Pharmaceutical Preparations
- FTFT Business Services
- Sector
- LIXT Health Care
- FTFT Consumer Discretionary
- Exchange
- LIXT Nasdaq
- FTFT Nasdaq
- Market Cap
- LIXT 12.4M
- FTFT 11.0M
- IPO Year
- LIXT N/A
- FTFT N/A
- Fundamental
- Price
- LIXT $5.63
- FTFT $2.11
- Analyst Decision
- LIXT
- FTFT
- Analyst Count
- LIXT 0
- FTFT 0
- Target Price
- LIXT N/A
- FTFT N/A
- AVG Volume (30 Days)
- LIXT 167.8K
- FTFT 403.7K
- Earning Date
- LIXT 11-11-2025
- FTFT 08-19-2025
- Dividend Yield
- LIXT N/A
- FTFT N/A
- EPS Growth
- LIXT N/A
- FTFT N/A
- EPS
- LIXT N/A
- FTFT N/A
- Revenue
- LIXT N/A
- FTFT $2,368,206.00
- Revenue This Year
- LIXT N/A
- FTFT N/A
- Revenue Next Year
- LIXT N/A
- FTFT N/A
- P/E Ratio
- LIXT N/A
- FTFT N/A
- Revenue Growth
- LIXT N/A
- FTFT N/A
- 52 Week Low
- LIXT $0.64
- FTFT $1.01
- 52 Week High
- LIXT $6.26
- FTFT $5.70
- Technical
- Relative Strength Index (RSI)
- LIXT 65.38
- FTFT 46.78
- Support Level
- LIXT $5.40
- FTFT $2.00
- Resistance Level
- LIXT $6.26
- FTFT $3.88
- Average True Range (ATR)
- LIXT 0.63
- FTFT 0.45
- MACD
- LIXT 0.14
- FTFT -0.01
- Stochastic Oscillator
- LIXT 78.28
- FTFT 14.08
About LIXT Lixte Biotechnology Holdings Inc.
Lixte Biotechnology Holdings Inc is a biopharmaceutical company dedicated to improving patients' lives by developing a drug class called Protein Phosphatase 2A inhibitors. Its product pipeline is focused on inhibitors of protein phosphatase 2A, used in combination with cytotoxic agents and/or x-rays, immune checkpoint blockers, and other cancer therapies. The Company believes that inhibitors of protein phosphatases have therapeutic potential for a broad range of cancers. It focuses on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity at doses that produce little or no toxicity.
About FTFT Future FinTech Group Inc.
Future FinTech Group Inc is engaged in the financial technology business. The company participates in supply chain financing services and trading in China, asset management business in Hong Kong, and cross-border money transfer services in the United Kingdom. It has also expanded into brokerage and investment banking business in Hong Kong and a cryptocurrency mining farm in the U.S. The company's reportable segments include asset management services, supply chain financing and trading, and others.